TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: level of smoking cessation interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reaction to nPLA and rPLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific serum IgE to BV, nPLA, and rPLA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to resolution of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OM grade reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for class III melanocytic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discordance rates between TM and WSI interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mitotic figures detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of delta‐delta Fridericia corrected QT (∆∆QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prolongation of delta‐delta study‐specific corrected QT (∆∆QTcS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Central Subfield Thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EULAR response at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative probability of ETV resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative probability of viral breakthrough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheezing reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intramuscular temperature decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate variability increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of fentanyl doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: salivary sugar clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MLHFQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of cardiovascular death and myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: AOD hospital events
Endpoint domain: Mortality/survival
Primary endpoint: tolerance of the drug
Endpoint domain: Adverse events/effects
Primary endpoint: systolic, mean arterial and diastolic blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pharmacokinetic parameters (half-life, clearance, volume of distribution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative gastrointestinal quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Morning SBP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning DBP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BRS decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cure rate of O viverrini infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Egg reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reherniation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prosthesis removal due to infection
Endpoint domain: Adverse events/effects
Primary endpoint: Partial response (haemoglobin increment ≥2 g/dL from baseline)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of transferrin saturation to 25% or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Not smoking in the past 7 days at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Not smoking in the past 7 days at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of late pregnancy 7- and 30-day point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behaviour Rating Scale of the BSID‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fagan test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained attention test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: vaspin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: state anxiety/subjective distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reported fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: avoidant behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Development of angiographic CME after 36 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Development of angiographic CME after 140 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: time to first passage of flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FVC, FEV1 and PEF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Doctor-diagnosed food allergy
Endpoint domain: Adverse events/effects
Primary endpoint: DPP-IV inhibition at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GLP-1 levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hour urinary free cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: oral candidiasis rates
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal heart rate baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciliary detachment
Endpoint domain: Adverse events/effects
Primary endpoint: Mean VAS score for headache on day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients discontinuing treatment due to side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenic response to 2009 H1N1 vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of vaccine combinations
Endpoint domain: Adverse events/effects
Primary endpoint: oncologic benefit of pLA
Endpoint domain: Mortality/survival
Primary endpoint: Atrial Fibrillation Effect on Quality of Life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HOMA%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-test capillary blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: trial completion times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wasteful actions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medication drawer visibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exceeding SBP PLoC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Half-life of (+)-catechin in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (c(max)) of (+)-catechin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration (t(max)) of (+)-catechin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AXa blood level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: increased serum lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PASI 50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean time to PASI 50 or PASI 75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deployment success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological response (MR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔPaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total prostate cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: High-grade prostate cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Crusting
Endpoint domain: Adverse events/effects
Primary endpoint: Synechia
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperations for leaks
Endpoint domain: Adverse events/effects
Primary endpoint: first major CV events
Endpoint domain: Mortality/survival
Primary endpoint: Self-perceived consumption of low saturated fat foods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intentions to change diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in QMG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume normal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cycles with breakthrough bleeding and/or spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction at Cycle 6
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduced mortality at day 14
Endpoint domain: Mortality/survival
Primary endpoint: decreased mean Sepsis-related Organ Failure Assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased antibiotic use (mean number of antibiotic-free days)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cumulative PCA morphine used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAI rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean reduction in TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success after 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor functionality improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic intervention acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: electrocution pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No sternal pain after coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life scores (36-Item Short Form Health Survey)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total 90-day costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CSF glycine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of gross hematuria
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of ureteral complications
Endpoint domain: Adverse events/effects
Primary endpoint: Time to identify hazards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification order of hazards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication treatment adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptive vocabulary development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grafted volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory rate (rr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Health care provider satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall daily physical activity counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes per day of moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal anxiety on the Identification With a Motherhood Role scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prenatal anxiety on the Preparation for Labor scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Childhood neurodevelopmental scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, myocardial infarction, stroke, noncerebral systemic emboli, or major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Relative clopidogrel induced platelet inhibition (P-selectin-expression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical reduction of nasal blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in clinic PNIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocyte rates in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of PMN granulocyte elastase in seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of death, stroke, or bleeding
Endpoint domain: Mortality/survival
Primary endpoint: future nicotine dependence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of quitters
Endpoint domain: Mortality/survival
Primary endpoint: ICG-R scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress and anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fever resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of complete motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to obtain complete sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: RBC %EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of glycerol and free fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Ra and glucose rate of disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting energy expenditure and fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of zinc and Triclosan in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pH drop reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mild to moderate infections
Endpoint domain: Adverse events/effects
Primary endpoint: Use of sunglasses
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Signs of infection in ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Progression to healing of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Length of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Duration of abdominal pain resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of vomiting resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of diarrhea resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cholestasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of mutans streptococci colony count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of ventilator-associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of tracheal colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Episode of endotracheal tube occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: Volumetric measurement of the foot, ankle, and lower leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF12v2 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinically relevant weight loss (5% or more)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: attrition rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Repeatable Battery for the Assessment of Neuropsychological Status total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: treatment-related sICH
Endpoint domain: Adverse events/effects
Primary endpoint: Gleason score category diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time(EI)95
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean induction to delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of failed induction of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: repeat spontaneous preterm delivery at less than 37 weeks' gestation
Endpoint domain: Mortality/survival
Primary endpoint: Decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vibration perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: modified Rankin score at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTcF duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of postoperative bile leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of LP (Late Potentials)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attainment of LDL-C levels less than 70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum total bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of daily bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hemostasis without needing re-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for re-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Excessive Daytime Sleepiness (EDS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Smoking-cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous abstinence rates (CARs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence (PP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of CD4+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of CD8+ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes